TP53 and cancer: Therefore, we hypothesized that targeting O-GlcNAcylation in combination with chemotherapy could be a promising synthetic lethality approach for MSI/dMMR/p53 unmutated CRC treatment, abolishing the risk of senescence escape and cancer relapse.